CN102725278A - 双功能共缀物的化学合成及抗肿瘤与抗肿瘤转移作用 - Google Patents

双功能共缀物的化学合成及抗肿瘤与抗肿瘤转移作用 Download PDF

Info

Publication number
CN102725278A
CN102725278A CN201180007150XA CN201180007150A CN102725278A CN 102725278 A CN102725278 A CN 102725278A CN 201180007150X A CN201180007150X A CN 201180007150XA CN 201180007150 A CN201180007150 A CN 201180007150A CN 102725278 A CN102725278 A CN 102725278A
Authority
CN
China
Prior art keywords
tumor
conjugate
chemical synthesis
metastatic effects
dual functional
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CN201180007150XA
Other languages
English (en)
Other versions
CN102725278B (zh
Inventor
刘刚
赵楠
马瑶
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Beijing Xiehe Pharmaceutical Second Factory Co ltd
Institute of Materia Medica of CAMS
Original Assignee
Institute of Materia Medica of CAMS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Institute of Materia Medica of CAMS filed Critical Institute of Materia Medica of CAMS
Priority to CN201180007150.XA priority Critical patent/CN102725278B/zh
Priority to CN201210361323.4A priority patent/CN102964425B/zh
Priority to CN201210361925.XA priority patent/CN103204901B/zh
Publication of CN102725278A publication Critical patent/CN102725278A/zh
Application granted granted Critical
Publication of CN102725278B publication Critical patent/CN102725278B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
    • C07K5/0215—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing natural amino acids, forming a peptide bond via their side chain functional group, e.g. epsilon-Lys, gamma-Glu
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/542—Carboxylic acids, e.g. a fatty acid or an amino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/65—Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D305/00—Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms
    • C07D305/14—Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms condensed with carbocyclic rings or ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)

Abstract

本发明公开了一类式（I）所示的双功能共缀物的化学合成及抗肿瘤与抗肿瘤转移作用，具体为紫杉醇（Taxol）或多西紫杉醇（Docetaxel）与胞壁酰二肽（MDP）衍生物形成的共缀物，将紫杉醇或多西紫杉醇与强效免疫增强剂胞壁酰二肽简化物进行相连，实现了化学治疗与免疫治疗相结合的抗肿瘤与抗肿瘤转移的双重功效。本发明结合固相合成和液相合成的方法合成了多个紫杉醇或多西紫杉醇和胞壁酰二肽简化物的共缀物，并通过可靠的生物学实验方法及数据证明该类共缀物能用于制备抗肿瘤。

Description

PCT国内申请，说明书已公开。

Claims (1)

  1. PCT国内申请，权利要求书已公开。
CN201180007150.XA 2010-05-27 2011-05-27 紫杉醇与胞壁酰二肽简化物的共缀物及抗肿瘤与抗肿瘤转移作用 Active CN102725278B (zh)

Priority Applications (3)

Application Number Priority Date Filing Date Title
CN201180007150.XA CN102725278B (zh) 2010-05-27 2011-05-27 紫杉醇与胞壁酰二肽简化物的共缀物及抗肿瘤与抗肿瘤转移作用
CN201210361323.4A CN102964425B (zh) 2010-05-27 2011-05-27 多西紫杉醇与胞壁酰二肽简化物的共缀物及抗肿瘤作用
CN201210361925.XA CN103204901B (zh) 2010-05-27 2011-05-27 紫杉醇共缀物的制备方法

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
CN2010101845416 2010-05-27
CN201010184541 2010-05-27
CN201010184541.6 2010-05-27
CN201180007150.XA CN102725278B (zh) 2010-05-27 2011-05-27 紫杉醇与胞壁酰二肽简化物的共缀物及抗肿瘤与抗肿瘤转移作用
PCT/CN2011/074817 WO2011147330A1 (zh) 2010-05-27 2011-05-27 双功能共缀物的化学合成及抗肿瘤与抗肿瘤转移作用

Related Child Applications (3)

Application Number Title Priority Date Filing Date
CN201210361925.XA Division CN103204901B (zh) 2010-05-27 2011-05-27 紫杉醇共缀物的制备方法
CN201310015256.5A Division CN103183724B (zh) 2010-05-27 2011-05-27 多西紫杉醇共缀物的制备方法
CN201210361323.4A Division CN102964425B (zh) 2010-05-27 2011-05-27 多西紫杉醇与胞壁酰二肽简化物的共缀物及抗肿瘤作用

Publications (2)

Publication Number Publication Date
CN102725278A true CN102725278A (zh) 2012-10-10
CN102725278B CN102725278B (zh) 2015-06-24

Family

ID=45003329

Family Applications (4)

Application Number Title Priority Date Filing Date
CN201210361323.4A Expired - Fee Related CN102964425B (zh) 2010-05-27 2011-05-27 多西紫杉醇与胞壁酰二肽简化物的共缀物及抗肿瘤作用
CN201310015256.5A Expired - Fee Related CN103183724B (zh) 2010-05-27 2011-05-27 多西紫杉醇共缀物的制备方法
CN201210361925.XA Active CN103204901B (zh) 2010-05-27 2011-05-27 紫杉醇共缀物的制备方法
CN201180007150.XA Active CN102725278B (zh) 2010-05-27 2011-05-27 紫杉醇与胞壁酰二肽简化物的共缀物及抗肿瘤与抗肿瘤转移作用

Family Applications Before (3)

Application Number Title Priority Date Filing Date
CN201210361323.4A Expired - Fee Related CN102964425B (zh) 2010-05-27 2011-05-27 多西紫杉醇与胞壁酰二肽简化物的共缀物及抗肿瘤作用
CN201310015256.5A Expired - Fee Related CN103183724B (zh) 2010-05-27 2011-05-27 多西紫杉醇共缀物的制备方法
CN201210361925.XA Active CN103204901B (zh) 2010-05-27 2011-05-27 紫杉醇共缀物的制备方法

Country Status (7)

Country Link
US (1) US9085605B2 (zh)
EP (2) EP2612857B1 (zh)
JP (1) JP5922104B2 (zh)
KR (1) KR101477194B1 (zh)
CN (4) CN102964425B (zh)
RU (2) RU2729419C2 (zh)
WO (1) WO2011147330A1 (zh)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104177474A (zh) * 2014-08-22 2014-12-03 亚飞（上海）生物医药科技有限公司 一种肿瘤微环境靶向激活的多烯紫杉醇衍生物及其用途
WO2019047811A1 (zh) * 2017-09-07 2019-03-14 深圳信立泰药业股份有限公司 多西紫杉醇共缀物在制备预防或治疗各种免疫疾病的药物中的应用
US10682371B2 (en) 2014-08-22 2020-06-16 Yafei Shanghai Biolog Medicine Science & Technology Co. Ltd. Small molecule conjugates specifically activated in tumor microenvironment for targeting and use thereof

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105732592A (zh) * 2014-12-06 2016-07-06 北京瑞都医药科技有限公司 一种大环多胺药物及其制备方法
CN105418732A (zh) * 2015-12-02 2016-03-23 烟台海安药物研发有限公司 多西紫杉醇维瑞肽偶合物及其制备方法
CN107200771B (zh) * 2016-03-16 2024-04-16 深圳信立泰药业股份有限公司 多西紫杉醇与胞壁酰二肽简化物的共缀物的制备及抗肿瘤作用
CN106188273A (zh) * 2016-07-13 2016-12-07 烟台海安药物研发有限公司 紫杉醇伐普肽偶合物及其制备方法
CN106589055B (zh) * 2016-11-03 2020-07-28 清华大学 取代的细胞酰二肽类化合物及其制备方法和用途
JP7317804B2 (ja) * 2017-09-07 2023-07-31 シェンヅェン サルブリス ファーマシューティカルズ カンパニー リミテッド ドセタキセル結合体の医薬組成物及び調製方法
TWI634902B (zh) * 2017-10-28 2018-09-11 醫療財團法人徐元智先生醫藥基金會亞東紀念醫院 Use of glucosamine peptide compounds for the treatment of abnormal liver metabolism
CN112321684B (zh) * 2020-11-03 2022-09-20 红河学院 紫杉醇-抗菌肽偶合物、合成方法、抑制癌症活性的应用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1712399A (zh) * 2004-06-24 2005-12-28 中国医学科学院药物研究所 紫杉醇和免疫增强剂胞壁酰二肽共轭物的制备及用途

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5618996A (en) 1979-06-21 1981-02-23 Dai Ichi Seiyaku Co Ltd Muramyldipeptide derivative
JPS5920297A (ja) 1982-07-27 1984-02-01 Dai Ichi Seiyaku Co Ltd ムラミルジペプチド誘導体
FR2546756B1 (fr) 1983-06-03 1985-11-29 Centre Nat Rech Scient Nouveaux derives immunostimulants, leur preparation et leur application comme medicament
GB9213077D0 (en) 1992-06-19 1992-08-05 Erba Carlo Spa Polymerbound taxol derivatives
RU2083588C1 (ru) 1995-09-11 1997-07-10 Безруков Михаил Васильевич Способ получения мурамилпептидов
JP4808846B2 (ja) 1999-02-24 2011-11-02 ザ ユーエイビー リサーチ ファンデイション 癌の標的付けられた治療のためのタキサン誘導体
CZ20013519A3 (cs) 2000-02-02 2002-04-17 Florida State University Research Foundation, Inc. Taxany s C7 heterosubstituovaným acetátem jako protinádorové látky
US6596737B2 (en) 2000-02-02 2003-07-22 Fsu Research Foundation, Inc. C10 carbamoyloxy substituted taxanes
EP1165068B1 (en) 2000-02-02 2007-12-19 Florida State University Research Foundation, Inc. C10 heterosubstituted acetate taxanes as antitumor agents
US6822001B2 (en) * 2000-11-03 2004-11-23 Tularik Inc. Combination therapy using pentafluorobenzenesulfonamides and antineoplastic agents
EP1475105A1 (en) * 2003-05-09 2004-11-10 Schering AG Bone localising radiopharmaceutical and tubulin-interacting compound combinatorial radiotherapy
CN100522995C (zh) 2003-10-22 2009-08-05 中国医学科学院药物研究所 胞壁酰-丙氨酰-d-异谷氨酰胺衍生物、制法和其药物组合物与用途
DE102004027169B4 (de) 2004-06-03 2008-10-02 Daimler Ag Kraftfahrzeugfront mit Mitten-Abdeckung im Spoilerbereich zum verbesserten Kollisionsschutz von Fußgängern
US20060216767A1 (en) 2005-03-22 2006-09-28 Saladax Biomedical Inc. Docetaxel immunoassay
CN1687043A (zh) * 2005-04-04 2005-10-26 上海三维制药有限公司 一种紫杉醇及其类似物的制备方法
JP4779423B2 (ja) 2005-04-26 2011-09-28 パナソニック株式会社 振動型圧電加速度センサ素子とこれを用いた振動型圧電加速度センサ
US7976852B2 (en) * 2005-04-26 2011-07-12 Eisai R&D Management Co., Ltd. Compositions and methods for cancer immunotherapy
US7517485B2 (en) 2005-06-03 2009-04-14 Protective Industries, Inc. Liquid vinyl injection molding method and apparatus
TW200744603A (en) * 2005-08-22 2007-12-16 Chugai Pharmaceutical Co Ltd Novel anticancer concomitant drug
DK1969031T3 (da) * 2005-12-05 2009-09-14 Nitto Denko Corp Polyglutamat-aminosyre-konjugater og fremgangsmåder
CN100593024C (zh) * 2006-06-12 2010-03-03 上海龙翔生物医药开发有限公司 一种紫杉醇和多西紫杉醇的合成方法
WO2008010953A2 (en) * 2006-07-19 2008-01-24 University Of Georgia Research Foundation, Inc. Pyridinone diketo acids: inhibitors of hiv replication in combination therapy
CN101209350B (zh) 2006-12-30 2011-09-07 中国人民解放军军事医学科学院毒物药物研究所 以氨基酸为连接子的多聚谷氨酸-药物偶合物
ES2606505T3 (es) * 2007-01-12 2017-03-24 Ab Science Tratamiento de combinación de cánceres sólidos con antimetabolitos e inhibidores de tirosina quinasa
DE602007010232D1 (de) 2007-03-06 2010-12-16 Cell Therapeutics Europe Srl Verfahren zur Bestimmung der Menge konjugierten Taxans in Polyglutaminsäure-Taxan-Konjugaten
KR20100122510A (ko) 2008-03-06 2010-11-22 닛토덴코 가부시키가이샤 중합체 파클리탁셀 접합체 및 암 치료 방법
WO2009123481A1 (en) * 2008-04-01 2009-10-08 Virionyx Corporation Ltd Compositions and methods for treatment of neoplastic disease
WO2010042638A2 (en) 2008-10-07 2010-04-15 Young Bok Lee Hpma - docetaxel or gemcitabine conjugates and uses therefore
CZ303072B6 (cs) 2009-02-13 2012-03-21 Zentiva, K.S. Polymerní konjugáty paclitaxelu a docetaxelu s pH rízeným uvolnováním kancerostatika

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1712399A (zh) * 2004-06-24 2005-12-28 中国医学科学院药物研究所 紫杉醇和免疫增强剂胞壁酰二肽共轭物的制备及用途

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
XUQIN LI ET AL: "Chemical conjugation of muramyl dipeptide and paclitaxel to explore the combination of immunotherapy and chemotherapy for cancer", 《GLYCOCONJ J》, vol. 25, 27 December 2007 (2007-12-27), pages 415 - 425, XP019604670 *

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104177474A (zh) * 2014-08-22 2014-12-03 亚飞（上海）生物医药科技有限公司 一种肿瘤微环境靶向激活的多烯紫杉醇衍生物及其用途
US10682371B2 (en) 2014-08-22 2020-06-16 Yafei Shanghai Biolog Medicine Science & Technology Co. Ltd. Small molecule conjugates specifically activated in tumor microenvironment for targeting and use thereof
WO2019047811A1 (zh) * 2017-09-07 2019-03-14 深圳信立泰药业股份有限公司 多西紫杉醇共缀物在制备预防或治疗各种免疫疾病的药物中的应用
CN111757888A (zh) * 2017-09-07 2020-10-09 深圳信立泰药业股份有限公司 多西紫杉醇共缀物在制备预防或治疗各种免疫疾病的药物中的应用

Also Published As

Publication number Publication date
RU2012157041A (ru) 2014-07-10
EP3239139A1 (en) 2017-11-01
WO2011147330A1 (zh) 2011-12-01
EP2612857A1 (en) 2013-07-10
JP2013529218A (ja) 2013-07-18
KR20130042501A (ko) 2013-04-26
CN102964425B (zh) 2016-02-24
CN102964425A (zh) 2013-03-13
KR101477194B1 (ko) 2014-12-29
RU2729419C2 (ru) 2020-08-06
EP2612857A4 (en) 2014-07-23
CN103183724A (zh) 2013-07-03
CN103204901A (zh) 2013-07-17
RU2016143162A (ru) 2018-12-18
CN103204901B (zh) 2016-03-09
RU2016143162A3 (zh) 2020-01-23
RU2604718C2 (ru) 2016-12-10
JP5922104B2 (ja) 2016-05-24
US20130143826A1 (en) 2013-06-06
US9085605B2 (en) 2015-07-21
EP3239139B1 (en) 2020-10-28
CN102725278B (zh) 2015-06-24
EP2612857B1 (en) 2017-07-26
CN103183724B (zh) 2015-01-14

Similar Documents

Publication Publication Date Title
CN102725278A (zh) 双功能共缀物的化学合成及抗肿瘤与抗肿瘤转移作用
NZ588884A (en) Cross-linkers and their uses
WO2011138281A3 (de) Verfahren zur herstellung von dithiin-tetracarboxy-diimiden
MX2011008176A (es) Derivados de 3,3'-espiroindolinona como agentes anticancerigenos.
TW200800968A (en) Sulfoximine-substituted pyrimidines, processes for production thereof and use thereof as drugs
WO2012015681A3 (en) Drug-ligand conjugates, synthesis thereof, and intermediates thereto
WO2011039108A3 (en) Processes for preparing of glucopyranosyl-substituted benzyl-benzene derivatives
WO2009104021A3 (en) Novel polymorphs and processes for their preparation
MY153763A (en) Quinazolinedione derivatives, preparation thereof and therapeutic uses thereof
WO2010150211A3 (en) Use of derivatives of indoles for the treatment of cancer
WO2010088243A3 (en) Processes using molecular sieve ssz-79
WO2011126245A3 (en) Novel method of preparing vanadosilicate molecular sieve and novel vanadosilicate molecular sieve
WO2011001113A3 (fr) NOUVEAUX DERIVES DE 1,2,3,4-TETRAHYDRO-PYRIMIDO{1,2-a}PYRIMIDIN-6-ONE,LEUR PREPARATION ET LEUR UTILISATION PHARMACEUTIQUE
AU2010280497A8 (en) Anhydrate of tiotropium bromide
WO2011107948A3 (en) Ligands of insulin degrading enzyme and their uses
TN2012000105A1 (en) Spirolactam derivatives and uses of same
WO2011138265A3 (en) Indole and indazole derivatives as orexin receptor antagonists
WO2012082650A3 (en) Aminoglycosides:synthesis and use as antifungals
NZ603261A (en) Anticancer steroidal lactones unsaturated in position 7 (8)
EP3456837A3 (en) Decorin compositions and use thereof
WO2012015687A3 (en) Drug-ligand conjugates, synthesis thereof, and intermediates thereto
EP3290403A3 (en) Methods of producing molindone and its salts
WO2010080817A3 (en) Carbohydrate-cyclopamine conjugates as anticancer agents
WO2010013078A8 (en) Pyrrolidinyl-alkyl-amide derivatives their preparation and their therapeutic application as ccr3 receptor ligands
WO2011128699A3 (en) Novel process for the preparation of sunitinib

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
ASS Succession or assignment of patent right

Owner name: BEIJING XIEHE NO. 2 PHARMACEUTICAL FACTORY

Effective date: 20130411

C41 Transfer of patent application or patent right or utility model
TA01 Transfer of patent application right

Effective date of registration: 20130411

Address after: 100050 Beijing city Xuanwu District South Road No. 2

Applicant after: INSTITUTE OF MATARIA MEDICA, CHINESE ACADEMY OF MEDICAL SCIENCES

Applicant after: BEIJING XIEHE PHARMACEUTICAL SECOND FACTORY

Address before: 100050 Beijing city Xuanwu District Xiannongtan Street No. 1

Applicant before: INSTITUTE OF MATARIA MEDICA, CHINESE ACADEMY OF MEDICAL SCIENCES

C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
CP01 Change in the name or title of a patent holder
CP01 Change in the name or title of a patent holder

Address after: 100050 No. 2 Nanwei Road, Xuanwu District, Beijing

Patentee after: INSTITUTE OF MATARIA MEDICA, CHINESE ACADEMY OF MEDICAL SCIENCES

Patentee after: Beijing Xiehe Pharmaceutical Second Factory Co.,Ltd.

Address before: 100050 No. 2 Nanwei Road, Xuanwu District, Beijing

Patentee before: INSTITUTE OF MATARIA MEDICA, CHINESE ACADEMY OF MEDICAL SCIENCES

Patentee before: BEIJING XIEHE PHARMACEUTICAL SECOND FACTORY